NAVIGATING MEDICARE'S 2026 CHANGES

NAVIGATING MEDICARE'S 2026 CHANGES: A SURVIVAL GUIDE FOR PROSTATE CANCER PATIENTS

Special Report for the Informed Prostate Cancer Support Group Newsletter

Medicare is undergoing its most significant transformation in decades, with 2026 bringing both unprecedented challenges and unexpected opportunities for San Diego men with prostate cancer. While premiums are rising substantially, new reforms provide stronger protection against catastrophic drug costs than ever before.

THE CRITICAL SITUATION

Medicare Part D premiums are increasing dramatically as the federal government scales back premium subsidies. The Premium Stabilization Demonstration is reducing support from $15 to $10 monthly while allowing premium increases up to $50 (previously capped at $35). Combined with an 11.6% increase in Part B premiums to $206.50 monthly, most Medicare beneficiaries face significantly higher healthcare costs.

Simultaneously, major insurers are canceling Medicare Advantage plans nationwide. Aetna has discontinued nearly 90 plans across 34 states, UnitedHealthcare is dropping coverage for over 600,000 users, and locally, UC San Diego Health is terminating contracts with all Humana Medicare Advantage plans effective December 31, 2025.

THE BREAKTHROUGH: DRUG PRICE NEGOTIATIONS

Medicare's new negotiating power is delivering substantial savings. The first round of negotiations achieved 38% to 79% discounts on 10 high-cost medications, with beneficiaries expected to save $1.5 billion when new prices take effect January 1, 2026.

Enzalutamide (Xtandi) has been selected for the second round of negotiations. Along with 14 other drugs accounting for $41 billion in Medicare spending, enzalutamide will undergo price negotiations in 2025 with new prices effective in 2027. This represents a major victory for prostate cancer patients who have faced annual out-of-pocket costs ranging from $9,854 to $13,061 for this essential medication.

OUT-OF-POCKET PROTECTION STRENGTHENS

The annual spending cap increases from $2,000 in 2025 to $2,100 in 2026—still providing unprecedented protection for men taking expensive cancer medications. Before these reforms, Medicare research showed that average annual costs for metastatic prostate cancer reached $45,391 per patient, with about one-third ($8,756) attributed to Part D drug spending. The new cap eliminates this financial devastation.

The Part D deductible rises modestly from $590 to $615, while some positive changes emerge: certain plans now offer Tier 1 generics at $0 copay, and the Medicare Prescription Payment Plan allows spreading out-of-pocket costs across monthly installments.

MEDICARE ADVANTAGE DISRUPTIONS

Plan Cancellations Insurance companies cite rising medical costs and regulatory pressures as drivers behind widespread plan discontinuations. The cuts primarily affect PPO plans, which typically offer broader provider networks.

Local Impact UC San Diego Health patients enrolled in Humana Medicare Advantage plans face a critical decision. Three specific plans lose UC San Diego access after 2025:

• Humana Gold Plus Medicare Advantage HMO
• Humana UC San Diego Medicare Advantage HMO
• Humana USAA Honor with Rx PPO

Coverage Options After Plan Cancellation If your Medicare Advantage plan is cancelled, you have guaranteed rights:

• Automatic Protection: You'll be enrolled in Original Medicare if you don't choose a replacement
• Special Enrollment Period: Plan cancellations trigger additional enrollment opportunities
• Guaranteed Issue Rights: Access to Medigap policies without health underwriting

Original Medicare offers distinct advantages for cancer patients: unrestricted provider access, no prior authorization for most treatments, and stable coverage that doesn't change annually. However, you'll need separate Part D coverage and should consider Medigap insurance for comprehensive protection.

STRATEGIC RECOMMENDATIONS

Immediate Actions (Before December 7, 2025)

• Read your Annual Notice of Change carefully
• Use Medicare.gov/plan-compare to calculate total annual costs (premiums plus out-of-pocket expenses)
• UC San Diego Health patients on Humana plans must actively switch to maintain provider access
• Consider whether Original Medicare plus Medigap provides better stability than Medicare Advantage

Cost Analysis Approach Focus on total annual expenses rather than monthly premiums. For men taking enzalutamide, a higher-premium plan with better drug coverage may cost less overall than a low-premium plan. The $2,100 out-of-pocket cap makes premium differences less critical for expensive medication users.

Plan Selection Strategy

• Verify your oncologist and treatment facilities remain in-network
• Consider separate plans for spouses with different medication needs
• Evaluate Original Medicare for maximum provider flexibility and treatment access

RESOURCES AND SUPPORT

Free Local Assistance

• Health Insurance Counseling and Advocacy Program (HICAP) San Diego: 858-565-8772
• UC San Diego Health Medicare counseling: 619-471-9123
• Medicare Rights Center helpline: 800-333-4114

Key Tools

• Medicare Plan Finder: Medicare.gov/plan-compare
• Medicare general information: 1-800-MEDICARE (1-800-633-4227)

FUTURE OUTLOOK

The Inflation Reduction Act's 10-year implementation continues with CMS selecting up to 15 additional drugs for negotiation in 2028 and up to 20 drugs annually thereafter. This ongoing process should continue reducing cancer medication costs while the out-of-pocket caps provide immediate protection.

Medicare's transformation aims to balance access, quality, and affordability. While 2026 brings adjustment challenges, the combination of negotiated drug prices and spending caps creates the strongest financial protection Medicare has ever offered to cancer patients.

CONCLUSION

Despite higher monthly premiums, 2026's reforms fundamentally improve Medicare's value proposition for prostate cancer patients. The $2,100 spending cap and upcoming enzalutamide price negotiations address the core financial challenges of cancer treatment while maintaining access to life-saving therapies.

Success requires active engagement during open enrollment. Compare all options carefully, prioritize total annual costs over monthly premiums, and don't hesitate to seek professional guidance. The stakes are too high for passive decision-making.

---

SIDEBAR: THE POLITICAL PROMISE VS. POLICY REALITY

The current Medicare premium increases raise questions about how major healthcare reforms are communicated to the public versus how they actually function in practice.

What We Were Told in 2022 When the Inflation Reduction Act passed, the political messaging emphasized clear benefits:

• $2,000 annual cap would save money for patients with expensive medications
• Medicare would finally negotiate drug prices like other government programs
• $35 monthly insulin copay cap would provide immediate relief
• Overall healthcare costs would decrease

What Wasn't Prominently Discussed The technical details that policy experts understood but didn't feature in public communications:

• Insurers might shift costs from catastrophic coverage to monthly premiums
• The premium stabilization program was explicitly temporary (2025-2026 only)
• Market disruption as insurers reassess profitability and exit certain areas
• The fundamental trade-off: higher premiums for most in exchange for catastrophic protection for some

The Implementation Reality Congressional Budget Office analyses and Medicare actuaries certainly modeled these effects. The temporary nature of premium stabilization was written into the legislation, suggesting policymakers anticipated transition costs. However, these technical details remained buried in policy papers rather than becoming part of public discourse.

A Familiar Pattern This mirrors other major healthcare reforms where complex trade-offs get simplified in political messaging. The Affordable Care Act similarly emphasized coverage expansions while downplaying implementation challenges that later emerged.

The Bottom Line for Patients Whether the current situation represents unforeseen consequences or predictable trade-offs that weren't clearly communicated, the reality remains: Medicare beneficiaries face higher monthly costs in 2026 while gaining stronger protection against catastrophic expenses. For prostate cancer patients taking expensive medications, the math often works in their favor despite the premium shock. For healthy beneficiaries taking few medications, the trade-off is less favorable.

Understanding this context doesn't change the need to navigate 2026's choices carefully, but it does help explain why the current situation feels different from what many expected when the legislation passed.

---

Sources

1. Centers for Medicare & Medicaid Services. "2026 Medicare Part D Bid Information and Part D Premium Stabilization Demonstration Parameters." https://www.cms.gov/newsroom/fact-sheets/2026-medicare-part-d-bid-information-and-part-d-premium-stabilization-demonstration-parameters
2. Centers for Medicare & Medicaid Services. "HHS Announces 15 Additional Drugs Selected for Medicare Drug Price Negotiations." https://www.cms.gov/newsroom/press-releases/hhs-announces-15-additional-drugs-selected-medicare-drug-price-negotiations-continued-effort-lower
3. Centers for Medicare & Medicaid Services. "Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026." https://www.cms.gov/newsroom/fact-sheets/medicare-drug-price-negotiation-program-negotiated-prices-initial-price-applicability-year-2026
4. Urology Times. "Enzalutamide included in next round of Medicare drug price negotiations." January 17, 2025. https://www.urologytimes.com/view/enzalutamide-included-in-next-round-of-medicare-drug-price-negotiations
5. PMC. "Out-of-Pocket Costs for Prostate Cancer Medications Substantially Vary by Part D Plan: An Online Tool Presents an Opportunity to Mitigate Financial Toxicity." https://pmc.ncbi.nlm.nih.gov/articles/PMC10597673/
6. Wolters Kluwer. "New therapies have raised Medicare treatment costs for metastatic prostate cancer." December 22, 2022. https://www.wolterskluwer.com/en/news/new-therapies-have-raised-medicare-treatment-costs-for-metastatic-prostate-cancer
7. Kiplinger. "Medicare Costs Projected to Jump in 2026." August 14, 2025. https://www.kiplinger.com/retirement/medicare/plan-for-higher-health-care-costs-in-2026-projected-medicare-part-b-and-part-d-premiums
8. Yahoo Finance. "Medicare Advantage plans are scaling back." August 9, 2025. https://finance.yahoo.com/news/medicare-advantage-plans-are-scaling-back-090008599.html
9. UC San Diego Health. "Medicare Plans Accepted." https://health.ucsd.edu/insurance-billing/accepted-health-plans/medicare/
10. Pennsylvania Office of Rural Health. "Aetna Discontinues Medicare Advantage Plans in 2026." August 16, 2025. https://www.porh.psu.edu/aetna-discontinues-medicare-advantage-plans-in-2026/
11. Kaiser Family Foundation. "FAQs about the Inflation Reduction Act's Medicare Drug Price Negotiation Program." January 23, 2025. https://www.kff.org/medicare/faqs-about-the-inflation-reduction-acts-medicare-drug-price-negotiation-program/
12. Centers for Medicare & Medicaid Services. "Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program." April 4, 2025. https://www.cms.gov/newsroom/fact-sheets/contract-year-2026-policy-and-technical-changes-medicare-advantage-program-medicare-prescription-final
13.   Medicare Part D 2026: Changes Explained - YouTube

This newsletter article is for informational purposes only and does not constitute medical or financial advice. Consult with healthcare providers and Medicare counselors for personalized guidance.

IPCSG Newsletter: Medicare Part D 2026 Changes Impact Prostate Cancer Patients | Claude | Claude